By Neurotech Reports Staff
September 4, 2026 | News from across the neurotech and bioelectronic medicine sector including funding for wireless EEG, 25 years of Implanted Pulse Generators, new patents for Autonomix, Transcutaneous Auricular Neurostimulation for menstrual bleeding, Percutaneous Electrical Nerve Field Stimulation, funding updates, and more.
Epitel Closes $26 Million Series B to Expand Wireless EEG Monitoring
Epitel, Inc. has closed a $26 million Series B financing round co-led by Catalyst Health Ventures and Genoa Ventures, with participation from new and existing investors. The Salt Lake City-based company, a University of Utah spinout, will use the funds to expand commercial access to its REMI Remote EEG Monitoring System, a wireless, wearable platform that enables weeks-long at-home EEG monitoring paired with AI-driven seizure detection (REMI Vigilenz). The company says the funding addresses a major access gap: an estimated 9.2 million Americans experience seizures annually, but 40% lack access to EEG testing, in part because only 27% of U.S. hospitals have EEG capacity. REMI has received five FDA 510(k) clearances and is cleared for patients as young as one year old. Read the full release
Study Shows Brain Stimulation Safely Restores Touch
Researchers from the University of Pittsburgh and the University of Chicago report that intracortical microstimulation can safely restore a sense of touch over the long term, in the first and longest-running human safety study of its kind. Across five volunteers with spinal cord injuries, the team delivered 168 million pulses of brain stimulation via implanted brain-computer interface devices over a combined 27 years of implant time without any serious adverse events. Sensations stayed mapped to the hand rather than drifting to other body parts, rarely persisted after stimulation stopped, and electrodes remained functional in the majority of cases even after a decade. The findings, published in Science Translational Medicine, support the safety case for future clinical-grade BCIs designed to restore touch, hearing, or vision. Read the full release
Implanted Pulse Generators Hold Up Long-Term in Lower-Extremity Neuroprostheses
A new review in Neuromodulation from a Case Western Reserve University and Louis Stokes Cleveland VA research team examines 25 years of outcomes for implanted pulse generators (the IRS-8 and IST devices) used in lower-extremity motor neuroprostheses for people with paralysis from spinal cord injury or stroke. The authors report that most implanted devices have remained operational for over 25 years without needing removal or revision for clinical or technical reasons. About one-third of the research-grade devices were eventually explanted, driven by personal choice, infection, or technical issues rather than device failure. The study, led by Lizbeth Leapo, Michael Miller, and Ronald Triolo, supports the long-term durability of implanted neurostimulation systems for restoring standing, stepping, and other lower-limb functions. Read the paper
Neurolief Expands Veterans’ Access to Neuromodulation Through New VA Contract
Neurolief is bringing two prescription neuromodulation therapies to U.S. veterans through a new Department of Veterans Affairs contract: ProlivRx, an at-home brain stimulation therapy for adults with major depressive disorder who haven’t achieved adequate relief from antidepressants, and RelivionMG, for the acute treatment of migraine. VA sites have begun prescribing both therapies. Proliv Rx received FDA approval in December 2025 as the first prescription at-home brain neuromodulation therapy for treatment-resistant depression; in clinical trials, 61.7% of patients achieved clinically substantial improvement at eight weeks, compared with 32% in the sham group. Both therapies are non-invasive, stimulate cranial nerves, and are designed for physician-supervised home use. Read the full release
Autonomix Expands Its Precision Neuromodulation Patent Portfolio
Autonomix Medical (NASDAQ: AMIX) has been granted U.S. Patent No. 12,433,670, titled “Systems and Methods for Treating Cancer and/or Augmenting Organ Function.” The patent expands the company’s intellectual property protection around minimally invasive, catheter-based technologies designed to sense, map and selectively target nerves associated with tumors, cancer-related pain, organ function, and other autonomic nervous system disorders. Potential applications span multiple solid tumor types, including pancreatic, prostate, breast, colorectal, liver, ovarian, and bone cancers. The company says the patent builds on its existing IP covering autonomic nervous system assessment, neural sensing, treatment guidance, and transvascular neuromodulation, reinforcing its strategy of building a broad, defensible platform across oncology and autonomic nervous system disorders. Read the full release
Migraine Study Finds Nerivio Helps Patients Skip Prescribed Medications in 3 of 4 Attacks
Theranica has announced results from the largest and longest-running real-world evidence study of migraine treatment in the U.S. veteran population published to date. The peer-reviewed study, published in Military Medicine, analyzed nearly 30,000 real-world treatments and found that Nerivio, the company’s FDA-cleared Remote Electrical Neuromodulation (REN) wearable, gave veterans consistent relief from migraine while reducing reliance on prescribed migraine medications. Patients were able to successfully skip their prescribed medication in three out of four treated attacks. Nerivio is available to all eligible veterans through the VA and is listed on the Federal Supply Schedule. Theranica says the results strengthen the clinical case for non-pharmacological migraine care within federal health systems. Read the full release
ReVision Implant Closes Oversubscribed €4M Funding Round
The ReVision Implant team has closed an oversubscribed capital round worth approximately $4.6M. The company says the funding is a key step toward advancing the preclinical research it has conducted in recent years into clinical testing. See the LinkedIn Announcement
Science Corp. Names Nevada Sanchez as Executive Vice President of Engineering
Science Corporation, the neural engineering and brain-computer interface (BCI) company, has appointed Nevada Sanchez as Executive Vice President of Engineering. Sanchez will lead engineering across the organization and report directly to Science CEO and co-founder Max Hodak. Sanchez co-founded Butterfly Network in 2011 and most recently served as its Senior Vice President and Chief Innovation Officer, where he developed the world’s first ultrasound system on a chip. The appointment follows Science’s $230 million Series C raise and comes as the company begins the European commercial launch of PRIMA, its retinal implant designed to restore vision in patients with advanced macular degeneration, while continuing to develop implantable neural interfaces and organ-support technologies. Read the full release
Monteris Medical Publishes on NeuroBlate LITT
Monteris Medical has published the largest prospective dataset to date of patients undergoing laser interstitial thermal therapy (LITT), drawn from its LAANTERN study. Published in the Journal of Clinical Oncology, the analysis examines outcomes from 787 brain tumor patients treated exclusively with the company’s NeuroBlate System across 25 U.S. centers. The study found that extent of ablation is a critical determinant of survival, particularly for newly diagnosed glioblastoma and recurrent metastatic tumors, and that earlier intervention on metastatic tumors—while lesions are still small—confers a survival advantage. Patients also experienced short hospital stays, low complication and infection rates, and reduced reliance on steroids and anticonvulsant medications. Read the full release
Spark Biomedical Announces tAN Pilot Results
Spark Biomedical announced results from a pilot clinical trial evaluating its Transcutaneous Auricular Neurostimulation (tAN) therapy for the reduction of heavy menstrual bleeding (HMB), a condition affecting more than 10 million women in the United States. The open-label study, published in Bioelectronic Medicine, followed women with HMB across three menstrual cycles—one baseline cycle followed by two consecutive treatment cycles using tAN delivered through a wearable earpiece. Among participants who completed the full protocol, the therapy produced clinically meaningful improvements, including up to a 48% reduction in menstrual blood loss, a 68% decrease in overall menstrual symptoms, and a 62% reduction in pain-related symptoms, along with less fatigue and 70% less extra time spent in bed due to symptoms. Notably, outcomes improved across consecutive cycles, suggesting greater benefit with continued use. The tAN technology, delivered via Spark’s Sparrow Link device, stimulates branches of the vagus and trigeminal nerves through the ear to influence pathways tied to inflammation, pain, and hemostasis, and has now been evaluated in more than 30 clinical trials across a range of indications. Company leadership framed the findings as an early but important step toward non-hormonal, neuromodulation-based approaches to menstrual health, building on the broader momentum behind Spark’s consumer-facing OhmBody brand. Read the full study.
Seed Funding for Aurenar
Aurenar announced the close of an oversubscribed $5.7 million seed financing round, co-led by the Go Red for Women Venture Fund—part of American Heart Association Ventures—and Solas BioVentures, with additional participation from BJC Health and Kaleida Capital. The St. Louis-based company is developing V-Link, a non-invasive, single-use neuromodulation platform designed to reduce life-threatening complications in intensive care unit patients. V-Link, which recently received FDA breakthrough device designation, delivers transauricular vagus nerve stimulation to modulate the body’s inflammatory response to conditions such as subarachnoid hemorrhage, a stroke type that leaves roughly 40% of survivors with permanent disability. Proceeds from the round will fund continued development toward pivotal trials, including final device engineering, verification and validation testing, and regulatory submissions to the FDA. Investors pointed to the disproportionate impact of subarachnoid hemorrhage and related inflammatory conditions on women as a key driver behind their support, while Aurenar’s leadership, which grew the technology out of research at Washington University School of Medicine, described the raise as a pivotal step toward becoming a trial-ready company. Press release.
Strong Revenue for PENFS Company
NeurAxis reported record second quarter 2026 financial results, with revenue climbing 116% year over year to $1.9 million, up from $894,000 in the second quarter of 2025, the company’s strongest quarterly performance to date. The growth was driven largely by the Category I CPT code assignment for Percutaneous Electrical Nerve Field Stimulation (PENFS), effective January 1, 2026, which substantially expanded payer coverage for NeurAxis’s IB-Stim therapy. Unit deliveries rose 60% year over year, and gross margin expanded by 230 basis points to 85.9%, reflecting a greater share of devices sold at full reimbursement rates rather than through the company’s discounted financial assistance program. NeurAxis ended the quarter with a cash balance of $8.3 million. Company leadership characterized the results as evidence that NeurAxis has moved from an “access-creation phase” into an “execution phase,” pointing to growing commercial insurance coverage, expanding physician adoption, and a more focused commercial organization as the foundation for sustained long-term growth. Press release.
Medicare Advantage Coverage for Neurostimulation for Heart Failure
CVRx has announced that Devoted Health has issued a Medicare Advantage coverage policy for Barostim therapy, a neurostimulation therapy from CVRx for patients with heart failure. Devoted Health, a national health insurance company with the eighth largest Medicare Advantage enrollment in the U.S., provides coverage to approximately 466,000 Medicare Advantage members across 29 states. The new policy covers Barostim for patients meeting its current FDA-approved indication as well as patients enrolled in the BENEFIT-HF trial, the landmark heart failure study evaluating Barostim in a significantly expanded patient population initiated earlier this year. The Devoted Health policy builds on several other positive reimbursement developments for Barostim in 2026. In January, Category I CPT codes went into effect for the Barostim procedure, and the Centers for Medicare & Medicaid Services (CMS) approved Category B IDE coverage for patients enrolled in the BENEFIT-HF trial. In May, Humana issued a Barostim therapy coverage policy for Medicare Advantage members and patients enrolled in the BENEFIT-HF trial. Press release.
